Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 18775019)

1.

Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.

Hur C, Broughton DE, Ozanne E, Yachimski P, Nishioka NS, Gazelle GS.

Am J Gastroenterol. 2008 Oct;103(10):2432-42. doi: 10.1111/j.1572-0241.2008.02117.x. Epub 2008 Sep 4.

2.

Metformin use and the risk of esophageal cancer in Barrett esophagus.

Agrawal S, Patel P, Agrawal A, Makhijani N, Markert R, Deidrich W.

South Med J. 2014 Dec;107(12):774-9. doi: 10.14423/SMJ.0000000000000212.

PMID:
25502158
3.

Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.

Sharaiha RZ, Freedberg DE, Abrams JA, Wang YC.

Dig Dis Sci. 2014 Jun;59(6):1222-30. doi: 10.1007/s10620-014-3186-3. Epub 2014 May 3.

4.

[Radio frequency ablation of Barrett's esophagus--can the risk of esophageal adenocarcinoma be reduced?].

Salminen P, Räsänen J, Ristimäki A, Saarnio J, Heikkinen M, Laine S, Koivisto T, Färkkilä M.

Duodecim. 2014;130(6):557-64. Review. Finnish.

PMID:
24724454
5.

Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus.

Yachimski P, Wani S, Givens T, Howard E, Higginbotham T, Price A, Berman K, Hosford L, Katcher PM, Ozanne E, Perzan K, Hur C.

Clin Gastroenterol Hepatol. 2015 Jan;13(1):84-90. doi: 10.1016/j.cgh.2014.03.017. Epub 2014 Mar 26.

PMID:
24681073
6.

Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis.

Zhang S, Zhang XQ, Ding XW, Yang RK, Huang SL, Kastelein F, Bruno M, Yu XJ, Zhou D, Zou XP.

Br J Cancer. 2014 Apr 29;110(9):2378-88. doi: 10.1038/bjc.2014.127. Epub 2014 Mar 20.

7.

Symptoms and endoscopic features at barrett's esophagus diagnosis: implications for neoplastic progression risk.

Coleman HG, Bhat SK, Murray LJ, McManus DT, O'Neill OM, Gavin AT, Johnston BT.

Am J Gastroenterol. 2014 Apr;109(4):527-34. doi: 10.1038/ajg.2014.10. Epub 2014 Mar 4.

PMID:
24589668
8.

Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.

Peura DA, Wilcox CM.

Postgrad Med. 2014 Jan;126(1):87-96. doi: 10.3810/pgm.2014.01.2728. Review.

PMID:
24393755
9.

Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.

Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C.

Cancer Prev Res (Phila). 2014 Mar;7(3):341-50. doi: 10.1158/1940-6207.CAPR-13-0191-T. Epub 2013 Dec 31.

10.

Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.

Gaddam S, Singh M, Balasubramanian G, Thota P, Gupta N, Wani S, Higbee AD, Mathur SC, Horwhat JD, Rastogi A, Young PE, Cash BD, Bansal A, Vargo JJ, Falk GW, Lieberman DA, Sampliner RE, Sharma P.

Gastroenterology. 2013 Sep;145(3):548-53.e1. doi: 10.1053/j.gastro.2013.05.040. Epub 2013 May 25.

PMID:
23714382
11.

Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.

Anaparthy R, Gaddam S, Kanakadandi V, Alsop BR, Gupta N, Higbee AD, Wani SB, Singh M, Rastogi A, Bansal A, Cash BD, Young PE, Lieberman DA, Falk GW, Vargo JJ, Thota P, Sampliner RE, Sharma P.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1430-6. doi: 10.1016/j.cgh.2013.05.007. Epub 2013 May 22.

PMID:
23707463
12.

Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.

Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS.

Gastroenterology. 2013 Aug;145(2):312-9.e1. doi: 10.1053/j.gastro.2013.05.004. Epub 2013 May 11.

13.

MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.

Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E.

Cancer Prev Res (Phila). 2013 Mar;6(3):196-205. doi: 10.1158/1940-6207.CAPR-12-0276.

14.

Management strategies of Barrett's esophagus.

De Palma GD.

World J Gastroenterol. 2012 Nov 21;18(43):6216-25. doi: 10.3748/wjg.v18.i43.6216. Review.

15.

Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA).

Rugge M, Zaninotto G, Parente P, Zanatta L, Cavallin F, Germanà B, Macrì E, Galliani E, Iuzzolino P, Ferrara F, Marin R, Nisi E, Iaderosa G, Deboni M, Bellumat A, Valiante F, Florea G, Della Libera D, Benini M, Bortesi L, Meggio A, Zorzi MG, Depretis G, Miori G, Morelli L, Cataudella G, d'Amore ES, Franceschetti I, Bozzola L, Paternello E, Antonini C, Di Mario F, Dal Bò N, Furlanetto A, Norberto L, Polese L, Iommarini S, Farinati F, Battaglia G, Diamantis G, Realdon S, Guido E, Mastropaolo G, Canova D, Guerini A, Franceschi M, Zirillo M.

Ann Surg. 2012 Nov;256(5):788-94; discussion 794-5. doi: 10.1097/SLA.0b013e3182737a7e. Erratum in: Ann Surg. 2013 Mar;257(3):576. Dʼamore, Emanuele [corrected to d'Amore, Emanuele S G].

PMID:
23095623
16.

Natural history of Barrett's esophagus.

Milind R, Attwood SE.

World J Gastroenterol. 2012 Jul 21;18(27):3483-91. doi: 10.3748/wjg.v18.i27.3483. Review.

17.

A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'Zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ; Cancer Prevention Network.

Gastroenterology. 2012 Oct;143(4):917-26.e1. doi: 10.1053/j.gastro.2012.06.044. Epub 2012 Jul 11.

18.

[An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].

Zhang T, Su LW, Zhu YF, Lang HJ, Zhang F, Zhou YA, Liang XH, Wang YJ.

Zhonghua Wei Chang Wai Ke Za Zhi. 2012 May;15(5):512-6. Chinese.

PMID:
22648851
19.

The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM.

Gastroenterology. 2012 Sep;143(3):567-75. doi: 10.1053/j.gastro.2012.05.010. Epub 2012 May 21.

20.

Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.

Beales IL, Vardi I, Dearman L.

Eur J Gastroenterol Hepatol. 2012 Aug;24(8):917-23. doi: 10.1097/MEG.0b013e3283543f01.

PMID:
22569083
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk